Gilead Sciences, Inc. (BMV:GILD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 2.81T +16.6% |
| Revenue (ttm) | 536.07B +3.5% |
| Net Income | 166.14B +54.5% |
| EPS | 132.55 +55.4% |
| Shares Out | n/a |
| PE Ratio | 16.93 |
| Forward PE | n/a |
| Dividend | 58.43 (2.56%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 7 |
| Average Volume | 1,741 |
| Open | 2,246.00 |
| Previous Close | 2,280.00 |
| Day's Range | 2,246.00 - 2,246.00 |
| 52-Week Range | 2,025.32 - 2,618.71 |
| Beta | 0.33 |
| RSI | 41.69 |
| Earnings Date | May 7, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
US FDA approves Gilead's drug for deadly liver infection
The U.S. Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver infection that previously had no approved treatment options.
Gilead receives positive CHMP opinion for Trodelvy in TNBC
Gilead (GILD) Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorization of Tr...
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ado...
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, inc...
Gilead completes acquisition of Tubulis for $3.15B upfront
Gilead (GILD) Sciences announced the completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibo...
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, c...
Gilead renews five-year collaboration with World Health Organization
Gilead (GILD) Sciences announced a renewed five-year collaboration with the World Health Organization, committing funding, strategic support and product donations to accelerate progress toward elimina...
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic sup...
RBC Capital remains ‘conservative’ on Gilead’s Trodelvy and Yeztugo
RBC Capital keeps a Sector Perform rating and $122 price target on Gilead (GILD) after hosting the RBC healthcare conference with a presentation by the company CMO. There was high…
Gilead upgraded to Buy at Maxim on approaching growth drivers, valuation
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target The company’s growth in the base business is expected to reach 5%-6%, exceeding the…
Gilead upgraded to Buy from Hold at Maxim
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target
Gilead Sciences Transcript: RBC Capital Markets Global Healthcare Conference 2026
Key updates include positive Trodelvy data in breast and lung cancer, acquisition of Tubulis for novel ADCs, and expansion of anito-cel CAR T into earlier myeloma lines. The inflammation portfolio is advancing, and HIV prevention/treatment options are expanding with once-yearly and weekly regimens.
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
Gilead Sciences NASDAQ: GILD Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammat...
Gilead Prices $3 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, tod...
Gilead to present new data on PBC, viral hepatitis at EASL 2026
Gilead (GILD) Sciences will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver Congress, May 27-30, 2026, Barcelona. These...
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of t...
Gilead Sciences Transcript: Bank of America Global Healthcare Conference 2026
The session highlighted strong growth in HIV and oncology, with updated guidance and major acquisitions in cell therapy, ADCs, and inflammation. Long-acting HIV prevention and treatment products are driving market expansion, while oncology assets like Trodelvy and anito-cel are positioned for significant growth.
Gilead price target lowered to $168 from $175 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Gilead (GILD) to $168 from $175 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Gilead price target raised to $157 from $155 at Truist
Truist raised the firm’s price target on Gilead (GILD) to $157 from $155 and keeps a Buy rating on the shares. The company delivered Q1 top- and bottom-line beats with…
Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
Gilead Sciences Earnings Call Transcript: Q1 2026
Q1 2026 saw 8% year-over-year base business growth, led by HIV, oncology, and liver disease. YEZTUGO and TRODELVY outperformed, prompting a $400M increase in 2026 revenue guidance. Multiple acquisitions and regulatory milestones are set to further strengthen the pipeline.
Gilead Sciences Slides: Q1 2026
Gilead Sciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Gilead Sciences Earnings release: Q1 2026
Gilead Sciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Gilead Sciences Quarterly report: Q1 2026
Gilead Sciences has published its Q1 2026 quarterly earnings report on May 7, 2026.